Management of multiple myeloma and related-disorders: guidelines from the Italian Society of Hematology (SIE), Italian Society of Experimental Hematology (SIES) and Italian Group for Bone Marrow Transplantation (GITMO).

Abstract:

OBJECTIVES:Perceiving the need for rigorous recommendations to facilitate decisions concerning the management of patients with multiple myeloma (MM), the Italian Society of Hematology (SIE) and the two affiliate societies (SIES and GITMO) commissioned a project to develop guidelines for the therapy of MM using evidence-based knowledge and consensus formation techniques. METHODS:After a comprehensive systematic review of 1,450 papers, an Expert Panel formulated and graded sixty recommendations according to the supporting evidence. Evidence gaps were filled with twenty-two consensus-based statements. High grade recommendations (grade A) are reported below. RESULTS:Treatment should be immediately initiated in MM patients with related organ damage: those patients aged below 65 years who do not have severe co-morbidities should receive autologous stem cell transplantation, while patients not candidates for autologous stem cell transplantation should receive oral melphalan and prednisone. Interferon-a should not be associated with conventional chemotherapy, but it can be offered with or without steroids as a maintenance therapy to patients who have reached a plateau phase. High-dose dexamethasone-containing regimens or high-dose dexamethasone alone are recommended as a first-line therapy when cytoreduction is urgently required (i.e., MM with spinal cord compression or with rapidly progressive renal failure). MM patients with moderate-to-severe anemia should receive erythropoietin, while patients with bone disease or osteopenia should receive long-term bisphophonates. Recommendations for the management of the clinical manifestations caused by the monoclonal protein (i.e. hyperviscosity, cast nephropathy, AL amyloidosis) and of solitary bone and extramedullary plasmacytoma were also elaborated. CONCLUSIONS:A substantial proportion of clinical care for MM can be guided by evidence-based treatment recommendations.

journal_name

Haematologica

journal_title

Haematologica

authors

Barosi G,Boccadoro M,Cavo M,Corradini P,Marchetti M,Massaia M,Merlini G,Tosi P,Tura S,Italian Society of Hematology.,Italian Society of Experimental Hematology.,Italian Group for Bone Marrow Transplantation.

keywords:

subject

Has Abstract

pub_date

2004-06-01 00:00:00

pages

717-41

issue

6

eissn

0390-6078

issn

1592-8721

journal_volume

89

pub_type

杂志文章,实务指引,评审
  • In vivo and in vitro sensitivity of blastic plasmacytoid dendritic cell neoplasm to SL-401, an interleukin-3 receptor targeted biologic agent.

    abstract::Blastic plasmacytoid dendritic cell neoplasm is an aggressive malignancy derived from plasmacytoid dendritic cells. There is currently no accepted standard of care for treating this neoplasm, and therapeutic strategies have never been prospectively evaluated. Since blastic plasmacytoid dendritic cell neoplasm cells ex...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:10.3324/haematol.2014.111740

    authors: Angelot-Delettre F,Roggy A,Frankel AE,Lamarthee B,Seilles E,Biichle S,Royer B,Deconinck E,Rowinsky EK,Brooks C,Bardet V,Benet B,Bennani H,Benseddik Z,Debliquis A,Lusina D,Roussel M,Solly F,Ticchioni M,Saas P,Garna

    更新日期:2015-02-01 00:00:00

  • Age is a prognostic factor even among patients with multiple myeloma younger than 66 years treated with high-dose melphalan: the IFM experience on 2316 patients.

    abstract::Age is a strong prognostic factor in multiple myeloma. The overall survival is shorter in patients older than 66 years, and even shorter in those older than 75 years. Whether age is also a prognostic parameter in patients younger than 66 years treated homogeneously with intensive approaches is unknown. To address this...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:10.3324/haematol.2013.098608

    authors: Chretien ML,Hebraud B,Cances-Lauwers V,Hulin C,Marit G,Leleu X,Karlin L,Roussel M,Stoppa AM,Guilhot F,Lamy T,Garderet L,Pegourie B,Dib M,Sebban C,Lenain P,Brechignac S,Royer B,Wetterwald M,Legros L,Orsini-Piocelle

    更新日期:2014-07-01 00:00:00

  • Clonal stability of initial leukemia in a child with central nervous system relapse 7.4 years after bone marrow relapse of common acute lymphoblastic leukemic.

    abstract::Second central nervous system (CNS) relapses represent about 7.3% of subsequent recurrences of childhood acute lymphoblastic leukemia (ALL). In most children these subsequent CNS relapses occur during the first 18 months after diagnosis of the first relapse (mean 1.42 +/- 0.73 years). We present a patient who suffered...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:

    authors: Eckert C,Einsiedel HG,Hartmann R,von Stackelberg A,Völpel S,Guggemos A,Hanzsch N,Kawan L,Seeger K,Henze G

    更新日期:2004-07-01 00:00:00

  • The risk of recurrent venous thromboembolism among heterozygous carriers of factor V Leiden or prothrombin G20210A mutation. A systematic review of prospective studies.

    abstract::Factor V Leiden (FVL) and prothrombin G20210A mutation (PTM) are the two most common genetic polymorphisms known to predispose to a first episode of venous thromboembolism (VTE). However, whether these thrombophilic abnormalities are also risk factors for recurrent VTE is unclear. We conducted a systematic review of p...

    journal_title:Haematologica

    pub_type: 杂志文章,评审

    doi:10.3324/haematol.10234

    authors: Marchiori A,Mosena L,Prins MH,Prandoni P

    更新日期:2007-08-01 00:00:00

  • Deferasirox, deferiprone and desferrioxamine treatment in thalassemia major patients: cardiac iron and function comparison determined by quantitative magnetic resonance imaging.

    abstract:BACKGROUND:Oral deferiprone was suggested to be more effective than subcutaneous desferrioxamine for removing heart iron. Oral once-daily chelator deferasirox has recently been made commercially available but its long-term efficacy on cardiac iron and function has not yet been established. Our study aimed to compare th...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:10.3324/haematol.2009.019042

    authors: Pepe A,Meloni A,Capra M,Cianciulli P,Prossomariti L,Malaventura C,Putti MC,Lippi A,Romeo MA,Bisconte MG,Filosa A,Caruso V,Quarta A,Pitrolo L,Missere M,Midiri M,Rossi G,Positano V,Lombardi M,Maggio A

    更新日期:2011-01-01 00:00:00

  • Long-term safety and efficacy data on childhood venous thrombosis treated with a low molecular weight heparin: an open-label pilot study of once-daily versus twice-daily enoxaparin administration.

    abstract::In this open label pilot safety study 80 children over 3 months old with deep venous thrombosis were treated with enoxaparin with a target 4 h anti-factor Xa activity between 0.5-0.8 IU/mL. The children were stratified to receive once daily or twice daily doses. The study end-points were post-thrombotic syndrome, re-t...

    journal_title:Haematologica

    pub_type: 杂志文章,多中心研究

    doi:

    authors: Schobess R,Düring C,Bidlingmaier C,Heinecke A,Merkel N,Nowak-Göttl U

    更新日期:2006-12-01 00:00:00

  • Concordance of assays designed for the quantification of JAK2V617F: a multicenter study.

    abstract:BACKGROUND:Many different techniques have been designed for the quantification of JAK2V617F allelic burden, sometimes producing discrepant results. DESIGN AND METHODS:JAK2V617F quantification techniques were compared among 16 centers using 11 assays based on quantitative polymerase chain reaction (with mutation-specif...

    journal_title:Haematologica

    pub_type: 杂志文章,多中心研究

    doi:10.3324/haematol.13486

    authors: Lippert E,Girodon F,Hammond E,Jelinek J,Reading NS,Fehse B,Hanlon K,Hermans M,Richard C,Swierczek S,Ugo V,Carillo S,Harrivel V,Marzac C,Pietra D,Sobas M,Mounier M,Migeon M,Ellard S,Kröger N,Herrmann R,Prchal JT

    更新日期:2009-01-01 00:00:00

  • Allogeneic hematopoietic stem cell transplantation in myelofibrosis: the 20-year experience of the Gruppo Italiano Trapianto di Midollo Osseo (GITMO).

    abstract:BACKGROUND:Allogeneic stem cell transplantation is a potentially curative treatment for myelofibrosis, although its use is limited by a high rate of transplant-related mortality. In this study, we evaluated the outcome of patients with myelofibrosis who underwent allogeneic stem cell transplantation, and the impact of ...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:10.3324/haematol.12828

    authors: Patriarca F,Bacigalupo A,Sperotto A,Isola M,Soldano F,Bruno B,van Lint MT,Iori AP,Santarone S,Porretto F,Pioltelli P,Visani G,Iacopino P,Fanin R,Bosi A,GITMO.

    更新日期:2008-10-01 00:00:00

  • Update on chronic hepatitis C in hemophiliacs.

    abstract:BACKGROUND AND OBJECTIVES:Hepatitis C virus (HCV) infection is an important cause of morbidity and mortality in patients affected by hereditary bleeding disorders and treated with non-virus inactivated clotting factor concentrates during the 1970s. INFORMATION SOURCES:In this review, we briefly report the present know...

    journal_title:Haematologica

    pub_type: 杂志文章,评审

    doi:

    authors: Franchini M,Capra F,Tagliaferri A,Rossetti G,De Gironcoli M,Rocca P,Aprili G,Gandini G

    更新日期:2002-05-01 00:00:00

  • Salvage therapy with high-dose cytarabine and mitoxantrone in combination with all-trans retinoic acid and gemtuzumab ozogamicin in acute myeloid leukemia refractory to first induction therapy.

    abstract::Outcome of patients with primary refractory acute myeloid leukemia remains unsatisfactory. We conducted a prospective phase II clinical trial with gemtuzumab ozogamicin (3 mg/m(2) intravenously on day 1), all-trans retinoic acid (45 mg/m(2) orally on days 4-6 and 15 mg/m(2) orally on days 7-28), high-dose cytarabine (...

    journal_title:Haematologica

    pub_type: 杂志文章,多中心研究

    doi:10.3324/haematol.2015.141622

    authors: Hütter-Krönke ML,Benner A,Döhner K,Krauter J,Weber D,Moessner M,Köhne CH,Horst HA,Schmidt-Wolf IG,Rummel M,Götze K,Koller E,Petzer AL,Salwender H,Fiedler W,Kirchen H,Haase D,Kremers S,Theobald M,Matzdorff AC,Ganse

    更新日期:2016-07-01 00:00:00

  • Immunoglobulin heavy chain and T-cell receptor beta chain gene rearrangements in acute non lymphoid leukemia.

    abstract::The occurrence of immunoglobulin heavy chain (IgH) and/or T-cell receptor (TcR) gene rearrangements has been reported in some cases of acute non lymphoid leukemia (ANLL), and variously interpreted as reflecting "aberrant gene expression" or "lineage promiscuity" of the leukemic cell. In an attempt to verify the incide...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:

    authors: Leone R,Lo Coco F,De Rossi G,Diverio D,Frontani M,Spadea A,Testi AM,Cordone I,Mandelli F

    更新日期:1990-03-01 00:00:00

  • MOHITO, a novel mouse cytokine-dependent T-cell line, enables studies of oncogenic signaling in the T-cell context.

    abstract::The mouse pro-B cell line Ba/F3 has gained major interest as a model system to investigate oncogenic tyrosine kinases and to determine the efficacy of kinase inhibitors. While Ba/F3 cells are suitable to study oncogenic kinases derived from various cell types, the signaling networks in Ba/F3 cells are B-cell specific....

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:10.3324/haematol.2010.035931

    authors: Kleppe M,Mentens N,Tousseyn T,Wlodarska I,Cools J

    更新日期:2011-05-01 00:00:00

  • Clinical outcomes in children with sickle cell disease living in England: a neonatal cohort in East London.

    abstract:BACKGROUND AND OBJECTIVES:We investigated outcomes in a UK neonatal cohort as a benchmark for care of children with sickle cell disease (SCD). DESIGN AND METHODS:Two-hundred and fifty-two children (180 with hemoglobin [Hb] SS, 64 with HbSC, and 8 with HbS/beta thalassemia), identified during 1983-2005 by universal bir...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:10.3324/haematol.10937

    authors: Telfer P,Coen P,Chakravorty S,Wilkey O,Evans J,Newell H,Smalling B,Amos R,Stephens A,Rogers D,Kirkham F

    更新日期:2007-07-01 00:00:00

  • Flow cytometric analysis of neutrophil myeloperoxidase expression in peripheral blood for ruling out myelodysplastic syndromes: a diagnostic accuracy study.

    abstract::Suspicion of myelodysplastic syndromes (MDS) is one of the commonest reasons for bone marrow aspirate in elderly patients presenting with persistent peripheral blood (PB) cytopenia of unclear etiology. A PB assay that accurately rules out MDS would have major benefits. The diagnostic accuracy of the intra-individual r...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:10.3324/haematol.2018.202275

    authors: Raskovalova T,Berger MG,Jacob MC,Park S,Campos L,Aanei CM,Kasprzak J,Pereira B,Labarère J,Cesbron JY,Veyrat-Masson R

    更新日期:2019-12-01 00:00:00

  • Optimizing peripheral blood progenitor cell autologous transplantation in multiple myeloma.

    abstract::As in other malignancies, peripheral blood progenitor cells (PBPC) have almost completely replaced bone marrow as the source of stem cells for autologous transplantation in multiple myeloma. PBPC collection could be optimized either by reducing contamination by the malignant clone or by increasing hematopoietic qualit...

    journal_title:Haematologica

    pub_type: 临床试验,杂志文章,随机对照试验,评审

    doi:

    authors: Harousseau JL

    更新日期:1999-06-01 00:00:00

  • In vivo priming with granulocyte colony-stimulating factor possibly enhances the effect of gemtuzumab-ozogamicin in acute myeloid leukemia: results of a pilot study.

    abstract::Eight elderly patients with relapsed or refractory acute myeloid leukemia were treated sequentially with recombinant human granulocyte colony-stimulating factor with rhG-CSF and Mylotarg. Priming with rhG-CSF in vivo induced an increase in the proportion of CD33+ cycling blasts. Four patients (50% ) achieved a complet...

    journal_title:Haematologica

    pub_type: 信件

    doi:

    authors: Leone G,Rutella S,Voso MT,Fianchi L,Scardocci A,Pagano L

    更新日期:2004-05-01 00:00:00

  • The novel combination of sirolimus and bortezomib prevents graft-versus-host disease but maintains the graft-versus-leukemia effect after allogeneic transplantation.

    abstract:BACKGROUND:We have previously shown that bortezomib induces a depletion of alloreactive T cells and allows the expansion of T cells with suppressive properties. In the current study, we analyzed the potential synergistic effect of bortezomib in conjunction with sirolimus in order to reduce-graft-versus-host disease wit...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:10.3324/haematol.2011.058677

    authors: Caballero-Velázquez T,Sánchez-Abarca LI,Gutierrez-Cosio S,Blanco B,Calderon C,Herrero C,Carrancio S,Serrano C,del Cañizo C,San Miguel JF,Pérez-Simón JA

    更新日期:2012-09-01 00:00:00

  • Immune cell constitution in the tumor microenvironment predicts the outcome in diffuse large B-cell lymphoma.

    abstract::Tumor microenvironment (TME) and limited immune surveillance play important roles in lymphoma pathogenesis. Here, we aimed to characterize immunological profiles of diffuse large B-cell lymphoma (DLBCL), and predict the outcome in response to immunochemotherapy. We profiled the expression of 730 immune-related genes i...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:10.3324/haematol.2019.243626

    authors: Autio M,Leivonen SK,Brück O,Mustjoki S,Jørgensen JM,Karjalainen-Lindsberg ML,Beiske K,Holte H,Pellinen T,Leppä S

    更新日期:2020-02-20 00:00:00

  • Resistance to activated protein C as a risk factor of stroke in a thalassemic patient.

    abstract::It is well known that thalassemic patients exhibit an increased frequency of thrombotic events. Most individuals with resistance to activated protein C (APCR) are the result of a point mutation replacing Arg 506 with Gln in the factor V aminoacidic sequence (factor V Leiden). Recently APCR has been shown to account fo...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:

    authors: Giordano P,Sabato V,Schettini F,De Mattia D,Iolascon A

    更新日期:1997-11-01 00:00:00

  • Fluorescence in situ hybridization analysis of minimal residual disease and the relevance of the der(9) deletion in imatinib-treated patients with chronic myeloid leukemia.

    abstract::Forty-six patients with chronic myeloid leukemia receiving imatinib mesylate (39 in chronic phase, one in accelerated phase, and six in blastic crisis), were studied for a 20-62 month follow-up period by cytogenetics and fluorescence in situ hybridization using dual-color, dual-fusion BCR and ABL probes. This approach...

    journal_title:Haematologica

    pub_type: 信件

    doi:

    authors: Calabrese G,Fantasia D,Di Gianfilippo R,Stuppia L,Di Lorenzo R,Palka G

    更新日期:2006-07-01 00:00:00

  • B-cell involvement in chronic graft-versus-host disease.

    abstract::Chronic graft-versus-host disease is a serious complication in long-term survivors of allogeneic hematopoietic stem cell transplantation, with several organ systems affected. Chronic graft-versus-host disease is an important cause of morbidity and mortality in allogeneic hematopoietic stem cell transplantation. This a...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:10.3324/haematol.13311

    authors: Kapur R,Ebeling S,Hagenbeek A

    更新日期:2008-11-01 00:00:00

  • Association of 3q21q26 syndrome with different RPN1/EVI1 fusion transcripts.

    abstract:BACKGROUND AND OBJECTIVES:Patients with acute myeloblastic leukemia (AML) with features of myelodysplastic syndrome and abnormalities of megakaryocytopoiesis often have cytogenetic aberrations of 3q21 and 3q26 bands involving the paracentric inversion [inv(3) (q21q26)] or a reciprocal translocation [t(3;3) (q21;q26)]. ...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:

    authors: Martinelli G,Ottaviani E,Buonamici S,Isidori A,Borsaru G,Visani G,Piccaluga PP,Malagola M,Testoni N,Rondoni M,Nucifora G,Tura S,Baccarani M

    更新日期:2003-11-01 00:00:00

  • An international retrospective study for tolerability of 6-mercaptopurine on NUDT15 bi-allelic variants in children with acute lymphoblastic leukemia.

    abstract::Not available. ...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:10.3324/haematol.2020.266320

    authors: Tanaka Y,Yeoh AEJ,Moriyama T,Li CK,Kudo K,Arakawa Y,Buaboonnam J,Zhang H,Liu HC,Ariffin H,Chen Z,Kham SKY,Nishii R,Hasegawa D,Fujimura J,Keino D,Kondoh K,Sato A,Ueda T,Yamamoto M,Taneyama Y,Hino M,Takagi M,O

    更新日期:2021-01-28 00:00:00

  • Bone marrow transplantation for severe aplastic anemia: the Barcelona Hospital Clinic experience.

    abstract:BACKGROUND AND OBJECTIVE:The outcome of patients with severe aplastic anemia (SAA) has improved considerably over the last decades. Bone marrow transplantation (BMT) is the treatment of choice in young patients who have an HLA-identical sibling donor. This study analyzes the outcome and factors related to survival in p...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:

    authors: Hernández-Boluda JC,Marín P,Carreras E,Aguilar JL,Grañena A,Rozman C,Montserrat E

    更新日期:1999-01-01 00:00:00

  • Clinical phenotypes and molecular characterization of Hb H-Paksé disease.

    abstract:BACKGROUND AND OBJECTIVES:Hemoglobin Constant Spring (Hb CS), caused by a termination codon mutation (TAA-->CAA) in the a2 gene, is the most common non-deletional type of a thalassemia in Southeast Asia. This mutation can most easily be detected by loss of an MseI-restriction site (T/TAA) spanning the termination codon...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:

    authors: Viprakasit V,Tanphaichitr VS,Pung-Amritt P,Petrarat S,Suwantol L,Fisher C,Higgs DR

    更新日期:2002-02-01 00:00:00

  • The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale.

    abstract::A retrospective, international, multicenter study was undertaken to assess: (i) the prognostic role of 'interim' positron emission tomography performed during treatment with doxorubicin, bleomycin, vinblastine and dacarbazine in patients with Hodgkin lymphoma; and (ii) the reproducibility of the Deauville five-point s...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:10.3324/haematol.2013.103218

    authors: Gallamini A,Barrington SF,Biggi A,Chauvie S,Kostakoglu L,Gregianin M,Meignan M,Mikhaeel GN,Loft A,Zaucha JM,Seymour JF,Hofman MS,Rigacci L,Pulsoni A,Coleman M,Dann EJ,Trentin L,Casasnovas O,Rusconi C,Brice P,Bolis

    更新日期:2014-06-01 00:00:00

  • Soluble factors levels in the initial staging of high-grade non-Hodgkin's lymphomas.

    abstract::Plasma levels of several soluble factors were assayed in 31 untreated patients with high-grade non-Hodgkin's lymphomas (NHL). The results showed statistically significant higher average levels of interleukin-2 (IL-2), interleukin-6 (IL-6), interleukin-8 (IL-8), interleukin-2 receptor (IL-2r) and transferrin receptor (...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:

    authors: Stasi R,Conforti M,Del Poeta G,Simone MD,Coppetelli U,Tribalto M,Cantonetti M,Perrotti A,Venditti A,Papa G

    更新日期:1992-11-01 00:00:00

  • Hemojuvelin (HJV)-associated hemochromatosis: analysis of HJV and HFE mutations and iron overload in three families.

    abstract::Juvenile hemochromatosis is a severe form of hereditary iron overload. It can be caused by mutations in either hepcidin or hemojuvelin genes. In this study we identified the molecular basis of juvenile hemochromatosis in three Australian families and assessed the role of potential modifying genes in individuals carryi...

    journal_title:Haematologica

    pub_type: 信件

    doi:

    authors: Wallace DF,Dixon JL,Ramm GA,Anderson GJ,Powell LW,Subramaniam N

    更新日期:2005-02-01 00:00:00

  • Reducing transplant-related mortality after allogeneic hematopoietic stem cell transplantation.

    abstract:BACKGROUND AND OBJECTIVES:Transplant-related mortality (TRM) following allogeneic hematopoietic stem cell transplantation (HSCT) has been reported to be related to disease stage, duratiion of disease and type of donor. Furthermore, the outcome of transplants performed in the 1990s appears to be better than that of tran...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:

    authors: Bacigalupo A,Sormani MP,Lamparelli T,Gualandi F,Occhini D,Bregante S,Raiola AM,di Grazia C,Dominietto A,Tedone E,Piaggio G,Podesta M,Bruno B,Oneto R,Lombardi A,Frassoni F,Rolla D,Rollandi G,Viscoli C,Ferro C,Garba

    更新日期:2004-10-01 00:00:00

  • Salvage treatment with lenalidomide and dexamethasone in relapsed/refractory mantle cell lymphoma: clinical results and effects on microenvironment and neo-angiogenic biomarkers.

    abstract:BACKGROUND:Preclinical studies have highlighted the activity of lenalidomide in mantle cell lymphoma and its anti-proliferative synergy with dexamethasone. DESIGN AND METHODS:In this prospective, multicenter, phase II study, patients with relapsed/refractory mantle cell lymphoma who were not eligible for, or had relap...

    journal_title:Haematologica

    pub_type: 杂志文章,多中心研究

    doi:10.3324/haematol.2011.051813

    authors: Zaja F,De Luca S,Vitolo U,Orsucci L,Levis A,Salvi F,Rusconi C,Ravelli E,Tucci A,Bottelli C,Balzarotti M,Brusamolino E,Bonfichi M,Pileri SA,Sabattini E,Volpetti S,Monagheddu C,Vacca A,Ria R,Fanin R

    更新日期:2012-03-01 00:00:00